Abstract
We sought to determine factors that impact on the recovery of platelets after blood cell transplantation in patients with multiple myeloma. We performed retrospective analyses in 51 patients undergoing blood cell transplantation for multiple myeloma. The proportional-hazards model was applied to determine significant risk factors. Of 51 transplants, 14 patients failed to achieve a platelet count of 50 × 109/l. Median time to a neutrophil count of 0.5 × 109/l was 10.5 days. Median time to achieve a platelet count of 50 × 109/l was 32 days. Multivariate analysis revealed that cyclophosphamide and G-CSF priming before collection of hematopoietic precursors (P < 0.001) was a positive predictor of rapid engraftment and prior exposure to melphalan given orally (P = 0.02) was a negative predictor of subsequent platelet engraftment. The number of mononuclear cells collected, the patient’s disease status at the time of transplant and the presence of circulating plasma cells in the harvested product did not have a significant impact on time to platelet engraftment. We conclude that cyclophosphamide and G-CSF priming shortened the time to achieve platelet engraftment compared with G-CSF alone. Prior exposure to melphalan delayed platelet engraftment and can lead to complete failure of platelet recovery. Stem cells should be collected before melphalan administration in patients with multiple myeloma who are candidates for possible blood cell transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gertz, M., Lacy, M., Inwards, D. et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 20, 375–380 (1997). https://doi.org/10.1038/sj.bmt.1700897
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700897
Keywords
This article is cited by
-
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
Leukemia (2009)
-
First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma
Bone Marrow Transplantation (2005)
-
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
Bone Marrow Transplantation (2003)
-
Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)
Bone Marrow Transplantation (2000)